BMO Capital raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $28 from $24 and keeps an Outperform rating on the shares after a U.S. District court upheld the validity of the company’s ‘721 patent. Improved IP protection is likely to start to change the narrative around shares, giving investors confidence that Acadia revenue is stable in the long term, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $23 from $20 at Mizuho
- Acadia Pharmaceuticals price target raised to $31 from $28 at Baird
- ACADIA Pharmaceuticals’ Legal Victory and Pipeline Expansion Drive Buy Rating and Increased Price Target
- Acadia Pharmaceuticals price target raised to $32 from $27 at H.C. Wainwright
- Acadia court ruling alleviates overhang for Nuplazid, says RBC Capital